Helius Medical Technologies logo
Helius Medical Technologies HSDT
$ 1.92 -4.48%

Quarterly report 2025-Q3
added 11-18-2025

report update icon

Helius Medical Technologies Financial Ratios 2011-2026 | HSDT

Annual Financial Ratios Helius Medical Technologies

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.4 -0.0 -0.6 -1.1 -2.6 -6.0 -7.0 -10.8 -14.0 - - - -

P/S

5.5 0.1 21.8 24.3 17.3 356.6 - - - - - - -

EPS

-14.6 -52.1 -7.4 -11.8 -13.0 -1.3 -1.5 -0.1 -0.2 -0.0 -0.3 - -

EV (Enterprise Value)

3.7 M -5.34 M 3.24 M 15.4 M 24.9 M 163 M 204 M 75.9 M 123 M -16 K - - -

EBITDA per Share

-20.4 -57.2 -7.34 -11.7 -31.8 -40.9 -42.9 -24.1 -27.1 - - - -

EV/EBITDA

-0.1 -0.9 -0.9 -5.4 -8.3 -7.8 -14.1 - - - -

PEG

-0.0 -0.0 0.06 0.13 0.04 0.37 -0.06 0.29 -0.02 - - - -

P/B

1.5 0.0 1.0 4.1 4.4 17.3 -26.1 -4601.3 -79.9 - - - -

P/CF

-0.3 -0.0 -0.9 -1.4 -1.2 -8.5 -10.0 -9.4 -19.8 - - - -

ROE %

-376.60 -172.64 -161.09 -365.02 -167.63 -290.47 374.15 42501.31 569.11 - - - -

ROA %

-115.05 -81.40 -128.58 -215.82 -94.53 -102.86 -411.57 -170.31 -731.25 - - - -

ROCE %

-528.85 -190.36 -161.18 -348.92 -366.63 -270.70 305.11 -545.01 -47806.08 - - - -

Current Ratio

1.4 1.9 5.0 1.9 1.9 1.5 0.5 1.7 1.0 - - - -

DSO

53.3 31.8 48.9 127.0 140.0 210.0 - - - - - - -

DIO

327.4 419.8 529.7 365.9 258.0 - - - - - - - -

DPO

362.5 668.5 1112.1 702.7 723.1 - - - - - - - -

Operating Cycle

380.7 451.6 578.7 492.9 398.0 - - - - - - - -

Cash Conversion Cycle

18.2 -216.9 -533.5 -209.8 -325.0 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Helius Medical Technologies

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-32.89 -79.73 -0.51 - -744.35 -485.3 -3.08 - -5.49 -2.92 -4.42 - -2.9 -0.97 -1.15 - -2.01 -2.58 -1.65 - -2.7 -2.9 -5.38 - -0.22 -0.01 0.05 - -0.19 -0.78 -0.06 - -0.67 -0.31 -0.32 - -0.04 0.04 -0.05 -0.04 0.03 -0.01 - -0.04 -0.04 -0.1 -0.04 - - - - - - - - - - - -

EBITDA per Share

- - -0.53 - -820 -982 -4.17 - -4.67 -5.64 -6.73 - -13.5 -0.86 -1.2 - -1.84 -2.64 -1.7 - -2.82 -3.18 -4.48 - -0.22 -0.22 -0.26 - -0.21 -0.51 -0.23 - -0.31 -0.33 -0.29 - -0.04 -0.03 -0.04 -0.04 -0.01 -0.06 - -0.05 -0.05 -0.05 -0.04 - - - - - - - - - - - -

ROE %

-328.56 -657.07 -519.32 -249.14 -370.39 -394.62 -405.23 -198.40 -206.35 -93.05 -141.63 -153.53 -246.58 -331.69 -318.54 -192.79 -282.61 -279.38 -294.73 -299.54 -395.30 -401.25 -317.61 -76.26 -122.10 -72.18 -249.89 -238.56 -65.83 152.75 409.47 324.37 411.10 325.09 338.82 287.49 405.78 162.49 104.87 -6.34 -124.63 31.92 583.61 1167.23 1167.23 583.61 109091.26 217015.29 217015.29 108507.64 108507.64 - - - - - - - -

ROA %

-374.86 -366.74 -260.38 -127.92 -169.30 -144.67 -141.77 -74.83 -80.29 -44.38 -87.26 -108.85 -168.34 -222.36 -219.97 -138.22 -191.33 -184.95 -180.48 -177.10 -231.11 -232.01 -182.47 -43.01 -59.24 -21.47 -83.73 -84.48 -274.49 -448.27 -467.62 -356.81 -443.39 -339.95 -345.94 -286.99 -333.27 1.59 37.22 148.24 194.52 -53.76 -494.97 -989.94 -989.94 -494.97 -494.97 - - - - - - - - - - - -

ROCE %

-452.36 -582.75 -579.21 -330.72 -435.09 -432.33 -451.15 -237.57 -275.02 -208.09 -213.87 -177.64 -264.46 -313.83 -311.34 -189.94 -284.49 -292.22 -314.67 -294.08 -392.39 -396.14 -399.63 -314.84 -364.47 -315.79 -335.97 -217.31 -137.61 -8.28 191.38 226.76 325.22 343.97 325.22 244.19 382.34 347.52 440.51 355.87 217.72 154.08 516.40 1032.80 1032.80 516.40 516.40 - - - - - - - - - - - -

Current Ratio

0.8 4.2 1.6 1.4 3.1 3.5 1.5 1.4 1.5 1.7 1.8 1.9 3.2 3.2 3.9 5.0 2.8 4.6 5.3 2.5 2.5 2.5 2.5 2.3 2.3 2.3 2.3 1.6 1.6 1.6 1.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.7 0.4 0.4 0.4 - - - 0.5 - - - - - - - - - - - -

DSO

- - - - 130.6 42.6 56.1 - 75.9 27.6 33.7 - 7.0 26.4 30.3 - 31.0 64.3 66.8 - 51.5 50.8 62.6 - 127.8 37.0 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

1005.1 1071.2 810.3 - 389.1 465.9 312.0 - 264.5 292.6 451.0 - 535.8 568.8 366.5 - 554.4 674.8 2655.4 - 1613.5 554.6 445.9 - 613.1 257.4 191.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

1673.1 1199.1 793.4 - 495.3 812.4 498.9 - 261.8 351.1 548.6 - 728.6 1116.8 802.1 - 1049.9 1365.3 5596.7 - 3098.3 1065.1 1094.5 - 1718.4 721.4 786.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

1005.1 1071.2 810.3 - 519.8 508.5 368.1 - 340.4 320.2 484.7 - 542.7 595.2 396.7 - 585.4 739.1 2722.2 - 1665.0 605.4 508.5 - 740.9 294.4 217.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

-668.0 -127.8 17.0 - 24.5 -303.8 -130.8 - 78.6 -30.9 -63.9 - -185.9 -521.6 -405.4 - -464.5 -626.2 -2874.5 - -1433.3 -459.7 -586.1 - -977.5 -427.0 -569.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Helius Medical Technologies, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.55 -2.31 % $ 73.5 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 88.57 -0.65 % $ 18 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.93 -5.12 % $ 1.64 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.4 4.21 % $ 41.1 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 34.58 -5.62 % $ 1.07 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.59 -1.18 % $ 32.1 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.15 -5.29 % $ 3.36 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 79.34 -3.36 % $ 46.4 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.2 -1.84 % $ 1.51 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.52 -5.08 % $ 364 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA
Myomo Myomo
MYO
$ 0.7 2.32 % $ 29.3 M usaUSA
Penumbra Penumbra
PEN
$ 335.1 -0.39 % $ 13 B usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 50.13 -0.63 % $ 1.47 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.17 -5.65 % $ 47.6 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
STRATA Skin Sciences STRATA Skin Sciences
SSKN
- - $ 6.6 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 3.82 -1.04 % $ 106 M australiaAustralia
AxoGen AxoGen
AXGN
$ 31.28 -3.01 % $ 1.44 B usaUSA
Delcath Systems Delcath Systems
DCTH
$ 8.97 -1.75 % $ 321 M usaUSA